3H-spiperone binding to lymphocytes in neuroleptic-naive-schizophrenia and the effect of neuroleptic treatment.
The aim of this study was to determine whether spiperone binding to lymphocytes could serve as a biological marker of susceptibility to schizophrenia and schizophrenic spectrum disorders or as a measure of response to neuroleptic treatment. Lymphocyte spiperone binding parameters (Bmax, KD) were assessed in 13 patients with schizophrenia and 4 patients with schizotypal personality disorder, all neuroleptic naive, and in 19 age- and sex-matched control subjects. A repeated determination was carried out in 11 of the schizophrenic subjects after several months of neuroleptic treatment. In addition, the binding characteristics of 12 of the schizophrenic/schizotypal patients were compared with those of 13 healthy family members and normal unrelated controls. No significant differences were detected between the schizophrenic subjects and controls before or after neuroleptic treatment or between the patients and their non-affected family members and controls.
Laufer
N
N
Geha Psychiatric Hospital and Felsenstein Medical Research Center, Petah Tiqva, Israel.
Spivak
B
B
Holdengreber
V
V
Zipser
J
J
Kosower
N
N
Ragolsky
M
M
Weizman
A
A
D000328:Adult; D014150:Antipsychotic Agents / Q000097:blood* / Q000627:therapeutic use*; D015415:Biomarkers; D005260:Female; D006801:Humans; D007700:Kinetics; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics; D013134:Spiperone / Q000097:blood* / Q000627:therapeutic use; D014316:Tritium
D014150:Antipsychotic Agents; D015415:Biomarkers; D014316:Tritium; D013134:Spiperone